The comprehensive instructional program Breast Cancer: New Horizons, Current Controversies covers the entire spectrum of breast cancer treatment. The management of breast cancer survivors, advances in diagnostic techniques, and disease mechanisms are some topics covered. The course’s main objective is to increase oncology-specific healthcare professionals’ clinical knowledge, proficiency, and skills. As a result, the curriculum is appropriate for all clinicians who treat patients with breast cancer, including medical, surgical, and radiation oncologists, general and breast surgeons, internists, physician assistants, nurse practitioners, and oncology nurses.
Learning Aims:
After doing this exercise, participants will be able to:
Apply current expert recommendations and knowledge of recent clinical data to patient selection for novel and upcoming medicines for advanced breast cancer.
Apply knowledge to the treatment of breast cancer in particular demographics (such as old and young women) and modify treatment choices as necessary for individual patients.
Make evidence-based therapeutic decisions for women who are candidates for neoadjuvant or adjuvant therapy and are aware of the limits of genetic testing. Where relevant, choose suitable risk assessment modalities.
Apply current clinical research and professional advice to the management of breast cancer patients who have mastectomy surgery, including the incorporation of surgical techniques, breast reconstruction choices, and post-mastectomy radiation if necessary.
Consider the need for fertility and lifestyle counseling among patients with breast cancer and survivors, and evaluate current practices with regard to symptom management during active treatment and in survivorship. If necessary, update current procedures.
Analyze your own personal and genetic risk factors for breast cancer, and use the right genetic tests to identify hereditary breast cancer.
Agenda
Thursday, July 20, 2023
8:00-8:15 AM
Welcoming Remarks
Harold Burstein, MD, PhD
SESSION I BREAST SURGERY
8:15-8:35 AM
Management of the Axilla
Monica Morrow, MD
8:35-8:55 AM
Reconstruction Options in 2023
Matthew Carty, MD
8:55-9:15 AM
Lymphatic Surgery
Michelle Coriddi, MD
9:15-9:30 AM
Q&A
9:30-9:55 AM
Lecture: The Future of Breast Cancer Pathology
Jorge Reis-Filho, MD, PhD, FRCPath
9:55-10:10 AM
Q&A
10:10-10:25 AM
Break
SESSION II GENETICS
10:25-10:45 AM
Prophylactic Surgery: Who, What, When?
Barbara Smith, MD, PhD
10:45-11:05 AM
Genetic Testing: Who, Which Test, When?
Judy Garber, MD, MPH
11:05-11:30 AM
Managing Hereditary Breast Cancer: What We Do; What We Still Don’t Know
Nadine Tung, MD
11:30-11:45 AM
Q&A
11:45 AM-1:00 PM
Lunch
*not provided
1:00-1:25 PM
Lecture: The Future of Breast Cancer Imaging and Screening
Constance Lehman, MD, PhD
1:25-1:40 PM
Q&A
SESSION III RADIATION THERAPY
1:40-2:00 PM
Schedules and Regimens
Jennifer Bellon, MD
2:00-2:20 PM
Postmastectomy Radiation
Rachel Jimenez, MD
2:20-2:40 PM
Oligometastatic Disease
Steven Chmura, MD, PhD
2:40-3:00 PM
Radiotherapy Options for Brain Metastases
Ayal Aizer, MD, MHS
3:00-3:15 PM
Q&A
3:15-3:30 PM
Break
3:30-3:55 PM
Lecture: The Future of Breast Cancer: Radiation Oncology
Bruce Haffty, MD, MS
3:55-4:10 PM
Q&A
4:10-5:10 PM
Tumor Board: Local Regional Therapy
Tari King, MD, FACS
Friday, July 21, 2023
SESSION IV ER POSITIVE BREAST CANCER
8:00-8:20 AM
Novel Agents: SERDS
Rinath Jeselsohn, MD
8:20-8:40 AM
Novel Agents: AKT Pathways
Alex Toker, PhD
8:40-9:00 AM
Male Breast Cancer
Jose Pablo Leone, MD
9:00-9:20 AM
Role of ADCs in ER+ Breast Cancer
Paolo Tarantino, MD
9:20-9:40 AM
Special Considerations in Premenopausal Women
Erica Mayer, MD, MPH
9:40-9:55 AM
Break
9:55-10:15 AM
Adjuvant Endocrine Therapy: How Long?
Heather Parsons, MD, MPH
10:15-10:35 AM
Adjuvant Therapy: CDK4/6 Inhibitors
Sarah Sammons, MD
10:35-10:55 AM
Adjuvant Therapy: Chemotherapy
Beverly Moy, MD, MPH
10:55-11:20 AM
Local Regional Considerations in Older Cancer Patients
Christina Minami, MD
11:20-11:35 AM
Q&A
11:35 AM-12:00 PM
Lecture: The Future of Breast Cancer Clinical Trials Designs
Nabihah Tayob, PhD
12:00-12:10 PM
Q&A
12:10-12:30 PM
Break
12:30-1:35 PM
Tumor Board: Advanced Breast Cancer
Moderator: Erica Mayer, MD, MPH
*Lunch Included
1:35-1:45 PM
Break
SESSION V TRIPLE NEGATIVE BREAST CANCER
1:45-2:05 PM
Where To With Immunotherapy
Sara Tolaney, MD, MPH
2:05- 2:25 PM
Treating Brain Metasteses
Nancy Lin, MD
2:25-2:45 PM
Antibody Drug Conjugates
Aditya Bardia, MD, MPH
2:45-3:10 PM
Lecture:The Future of Immunotherapy in Breast Cancer
Elizabeth Mittendorf, MD, PhD
3:10-3:20 PM
Q&A
Sara Tolaney, MD, MPH
Nancy Lin, MD
Aditya Bardia, MD, MPH
Elizabeth Mittendorf, MD, PhD
3:20-3:35 PM
Break
SESSION VI SURVIVORSHIP
3:35-3:55 PM
Pregnancy After Breast Cancer
Ann Partridge, MD, MPH
3:55-4:15 PM
Cannabinoids and Breast Cancer
Ilana Braun, MD
4:15-4:35 PM
Exercise, Diet and Breast Cancer
Jennifer Ligibel, MD
4:35-4:45 PM
Q&A
Ann Partridge, MD, MPH
Ilana Braun, MD
Jennifer Ligibel, MD
4:45-5:10 PM
Schlager Lecture: The Future of Breast Cancer and Genomic Tools and Testing
Fabrice Andre, MD, PhD
5:10-5:20 PM
Q&A
Saturday, July 22, 2023
TUMOR BOARD
8:00 – 9:00 AM
Tumor Board: Early Stage Breast Cancer
Hal Burstein, MD, PhD
9:00 – 9:30 AM
ASCO Highlights
Harold Burstein, MD, PhD
9:30 – 9:45 AM
Break
SESSION VII HER2 POSITIVE BREAST CANCER
9:45 – 10:05 AM
ADCs for HER2 Positive Tumors
Rachel Occhiogrosso Abelman, MD
10:05 – 10:25 AM
HER2 Testing
Laura Collins, MD
10:25 – 10:45 AM
Treatment for Early-Stage HER2 Positive Breast Cancer
Adrienne Waks, MD
10:45 -11:05 AM
Curing HER2+ Breast Cancer
Steven Isakoff, MD, PhD
11:05 – 11:20 AM
Q&A
11:20 -11:30 AM
Closing Remarks
Harold Burstein, MD, PhD
